The Fund aims to maximise long-term total return to investors by investing predominantly in undervalued European equities.
Name | % Net Assets |
---|---|
Total | 5.2% |
Nestle | 4.0% |
Novartis | 3.9% |
Total | 3.8% |
Sanofi-Aventis | 3.7% |
Sanofi-Aventis | 3.5% |
Vivendi | 3.3% |
Bayer | 2.9% |
Muenchener Rueck | 2.6% |
Repsol | 2.6% |
Key | % Net Assets |
---|---|
Total | 5.2% |
Nestle | 4.0% |
Novartis | 3.9% |
Total | 3.8% |
Other | 83.1% |
Date | 07-Dec-2018 |
---|---|
NAV | 182.64p |
Currency | GBP |
Change | -7.07p |
% | -3.74% |
YTD change | 182.64p |
YTD % | n/a |
Fund Inception | 01/02/2008 |
---|---|
Fund Manager | n/a |
TER | 1.69 (31-Jan-2014) |
Minimum Investment | |
---|---|
Initial | n/a |
Additional | £10 |
Savings | £10 |
Charges | |
---|---|
Initial | 4.00% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
No risk data available. |
You are here: research